1. Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study 
Torben Bjerregaard Larsen, MD, PhD, Lars Hvilsted Rasmussen, MD, PhD, Anders Gorst-Rasmussen, MSc, PhD, Flemming Skjøth, MSc, PhD, Deirdre A. Lane, PhD, Gregory Y.H. Lip, MD 
The American Journal of Medicine 
Volume 127, Issue 12, Pages e5 (December 2014)
DOI: /j.amjmed
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1
Flow chart showing how the study population was obtained from prescription purchase data. Boxes show number of purchases with number of unique subjects in parentheses. The final study population with prior stroke is displayed in dashed boxes. In the vitamin K antagonist (VKA)-experienced stratum, warfarin purchasers were sampled in a 2:1 ratio for each switcher to dabigatran (according to calendar month of purchase and duration of VKA-experience).
The American Journal of Medicine  , e5DOI: ( /j.amjmed )
Copyright © 2014 Elsevier Inc. Terms and Conditions

3. Figure 2
Crude cumulative incidence of the composite endpoint of stroke or transient ischemic attack, according to Vitamin K antagonist-experience and current treatment.
The American Journal of Medicine  , e5DOI: ( /j.amjmed )
Copyright © 2014 Elsevier Inc. Terms and Conditions